Advocacy for the establishment of a comprehensive strategy to reduce the “burden” of schizophrenic disorders;Plaidoyer pour la mise en place d'une stratégie globale pour atténuer le « fardeau » des troubles schizophréniques

Encephale

Volumn 42, Issue 5, 2016, Pages 476-483

  Leguay, D ^a  

^a CESAME   (France)

Author keywords

Burden; Care pathway; Early intervention; Mental health care system; Prevention; Psychosocial rehabilitation programmes; Recovery; Schizophrenia

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CHRONIC DISEASE; CULTURAL FACTOR; DIABETES MELLITUS; DISEASE EXACERBATION; DISEASE SEVERITY; EARLY INTERVENTION; EMOTIONAL STABILITY; EMPLOYMENT; EMPOWERMENT; FAMILY FUNCTIONING; FRANCE; FUNCTIONAL ASSESSMENT; GENETIC RISK; HEALTH CARE COST; HEALTH CARE SYSTEM; HEART DISEASE; HOUSING; HUMAN; INTEGRATION; INTERPERSONAL STRESS; LIFE EXPECTANCY; MENTAL HEALTH SERVICE; NEOPLASM; PATIENT ADVOCACY; PEER GROUP; PSYCHOEDUCATION; PSYCHOSOCIAL CARE; PSYCHOSOCIAL REHABILITATION; QUALITY OF LIFE; RELAPSE; RISK FACTOR; SCHIZOPHRENIA; SOCIAL SUPPORT; SUICIDE; COMPLICATION; COST OF ILLNESS; PSYCHOLOGY;

COST OF ILLNESS; EARLY MEDICAL INTERVENTION; HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84994876696     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.encep.2016.05.007     Document Type: Article

References (70)

1. [1] Clarke, M.C., Kelleher, I., Clancy, M., et al. Predicting risk and the emergence of schizophrenia. Psychiatr Clin N Am 35 (2012), 585–612.
2. [2] Coldefy, M., Analyser les disparités de prise en charge en psychiatrie. Force et faiblesses du système d'information. Audition du 5 juin 2013 – Mission d'information sur la santé mentale et l'avenir de la psychiatrie. 2013, Assemblée Nationale.
3. [3] McGrath, J.J., Lawlor, D.A., The search for modifiable risk factors for schizophrenia. Am J Psychiatry 168 (2011), 1235–1238 [Editorial].
4. [4] Auquier, P., Lançon, C., Rouillon, F., et al. Mortality in schizophrenia. Pharmacoepidemiol Drug Saf 15 (2006), 873–879 [John Wiley & Sons, Ltd. http://www.interscience.wiley.com/].
5. [5] Corruble, E., L'enjeu de la mortalité dans la schizophrénie. Therapie 63:3 (2008), 247–250.
6. [6] Purcell, S.M., Moran, J.M., Fromer, M., et al. A polygenic burden of rare disruptive mutations in schizophrenia. Nature 506 (2014), 185–190.
7. [7] Rivollier, F., Lotersztajn, L., Chaumette, B., et al. Epigenetics of schizophrenia: a review. Encéphale 40:5 (2014), 380–386, 10.1016/j.encep.2014.06.005 [Epub 2014 Aug 12].
8. [8] Smieskova, R., Marmy, J., Schmidt, A., et al. Do subjects at clinical high risk for psychosis differ from those with a genetic high risk? – A systematic review of structural and functional brain abnormalities. Curr Med Chem 20 (2013), 467–481.
9. [9] Teyssier, J.R., Prodromes de la schizophrénie : consensus ou confusion ?. Encéphale 39 (2013), S1–S7.
10. [10] Yung, A.R., Yuen, H.P., McGorry, P.D., et al. Mapping the onset of psychosis: the comprehensive assessment of at-risk mental States. Aust N Z J Psychiatry 39 (2005), 964–971.
11. [11] Gross, G., Huber, G., Klosterkötter, J., et al. BSABS (Bonn Scale for the assessment of basic symptoms). 2008, Shaker Verlag, Aachen.
12. [12] Yung, A.R., Nelson, B., Thompson, A., et al. The psychosis threshold in ultra-high risk (prodromal) research: is it valid?. Schizophr Res 120 (2010), 1–6.
13. [13] Fusar-Poli, P., Bonoldi, I., Yung, A.R., et al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 69 (2012), 220–229.
14. [14] Addington, J., Heinssen, R., Prediction and prevention of psychosis in youth at clinical high risk. Annu Rev Clin Psychol 8 (2012), 269–289 [download from http://www.annualreviews.org/].
15. [15] McGorry, P.D., Nelson, B., Amminger, G.P., et al. Intervention in individuals at ultra-high risk for psychosis. A review and future directions. J Clin Psychiatry 70:9 (2009), 1206–1212.
16. [16] Stafford, M.R., Jackson, H., Mayo-Wilson, E., et al. Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ, 346, 2013, f185, 10.1136/bmj.f185.
17. [17] Kaur, T., Cadenhead, K.S., Treatment implications of the schizophrenia prodrome. Curr Topics Behav Neurosci, 2010, 10.1007/7854_2010_56 [25 p. – © Springer-Verlag Berlin Heidelberg].
18. [18] Hutton, P., Taylor, P.J., Cognitive behavioural therapy for psychosis prevention: a systematic review and meta-analysis. Psychol Med, 2013, 1–20, 10.1017/S0033291713000354 [© Cambridge University Press].
19. [19] Morrison, A.P., French, P., Stewart, S.L.K., et al. Early detection and intervention evaluation for people at-risk of psychosis: multisite randomised controlled trial. BMJ, 344, 2012, e2233.
20. [20] Bourre, J.M., Acides gras oméga 3 alimentaires et neuropsychiatrie. OCL 11:4/5 (2004), 362–370.
21. [21] Mossaheb, N., et al. Effect of omega-3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective?. Schizophr Res, 2013, 10.1016/j.schres.2013.05.027.
22. [22] Castle, D., Psychosis before first onset?. MJA, 196(9), 2012, 557.
23. [23] Van Os, J., Murray, R.M., Can we identify and treat “schizophrenia light” to prevent true psychotic illness?. BMJ, 346, 2013, f304.
24. [24] Srihari, V., Shah, J., Keshavan, M.S., Is early intervention for psychosis feasible and effective?. Psychiatr Clin N Am 35 (2012), 613–631.
25. [25] Tandon, R., Nasrallah, H.A., Keshavan, M.S., Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future. Schizophr Res 122 (2010), 1–23.
26. [26] Tournier, M., Premiers épisodes psychotiques. Actualités cliniques et épidémiologiques. Encéphale Supplément 2 (2013), S74–S78.
27. [27] Marshall, M., Rathbone, J., Early intervention for psychosis. Cochrane(6), 2011, CD004718, 10.1002/14651858.CD004718.pub3.
28. [28] de Koning, M.B., Bloemen, O.J.N., van Amelsvoort, A.M.J., et al. Early intervention in patients at ultra-high risk of psychosis: benefits and risks. Acta Psychiatr Scand 119 (2009), 426–442.
29. [29] Tandon, N., Shah, J., Keshavan, M.S., et al. Attenuated psychosis and the schizophrenia prodrome: current status of risk identification and psychosis prevention. Neuropsychiatry 2:4 (2012), 345–353.
30. [30] Yung, A., Is it appropriate to treat people at high risk of psychosis?. MJA, 196(9), 2012, 10.5694/mja12.10668.
31. [31] Lines, E., L'intervention durant les premiers stades de la psychose – Projet d'intervention précoce en santé mentale chez les jeunes. 2000, Association Canadienne pour la Santé Mentale http://www.cmha.ca/.
32. [32] Boonstra, N., Klaassen, R., Sytema, S., et al. Duration of untreated psychosis and negative symptoms—A systematic review and meta-analysis of individual patient data. Schizophr Res 142 (2012), 12–19.
33. [33] Hill, M., Crumlish, N., Clarke, L., et al. Prospective relationship of duration of untreated psychosis to psychopathology and functional outcome over 12 years. Schizophr Res 141:2–3 (2012), 215–221.
34. [34] Marshall, M., Lewis, S., Lockwood, A., et al. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients. A Systematic review. Arch Gen Psychiatry 62 (2005), 975–983.
35. [35] Cascio, M.T., Cella, M., Preti, A., et al. Gender and duration of untreated psychosis. A systematic review and meta-analysis. Early Intervent Psychiatry 6 (2012), 115–127.
36. [36] Birchwood, M., Connor, C., Lester, H., et al. Reducing duration of untreated psychosis: care pathways to early intervention in psychosis services. Br J Psychiatry 203:1 (2013), 58–64.
37. [37] Giordana, J.Y., La stigmatisation en psychiatrie et en santé mentale. 2010, Elsevier Masson, Paris [264 p.].
38. [38] Roelandt, J.L., Caria, A., Benradia, I., et al. De l'autostigmatisation au processus de stigmatisation : à propos de l'enquête internationale. Santé Mentale en population générale, images et réalités en France et dans 17 pays. Psychol Soc Educ 4:2 (2012), 137–149.
39. [39] Gourevitch, R., Quelles sont les données de la littérature concernant la violence hétéro-agressive chez les personnes présentant une schizophrénie ? Audition Publique. 2010, Haute Autorité de santé, Paris, 43–54 [Texte des experts].
40. [40] Corruble, E., Hardy, P., Observance du traitement en psychiatrie. EMC, 2003, Elsevier Masson SAS, Paris [37-860-A-60. 6 p.].
41. [41] Charpentier, A., Goudemand, M., Thomas, P., L'alliance thérapeutique, un enjeu dans la schizophrénie. Encéphale 35:1 (2009), 80–89.
42. [42] Besnier, N., Gavaudan, G., Navez, A., et al. Approche clinique du suicide au cours de la schizophrénie (I). Identification des facteurs de risque. Encéphale 35 (2009), 176–181 [http://www.sciencedirect.com/].
43. [43] Petitjean, F., Les effets de la psychoéducation. Ann Med Psychol 169:3 (2011), 184–187.
44. [44] Harrow, M., Jobe, T.H., Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery?. Schizophr Bull 39:5 (2013), 962–965.
45. [45] Gut-Fayand, A., Dervaux, A., Olié, J.P., et al. Substance abuse and suicidality in schizophrenia: a common risk factor linked to impulisivity. Psychiatry Res 102 (2001), 65–72.
46. [46] Carra, G., Johnson, S., Bebbington, P., et al. The lifetime and past-year prevalence of dual diagnosis in people with schizophrenia across Europe: findings from the European Schizophrenia Cohort (EuroSC). Eur Arch Psychiatry Clin Neurosci 262 (2012), 607–616.
47. [47] Lemogne, C., Nabi, H., Melchior, M., et al. Mortality associated with depression as compared with other severe mental disorders: a 20-year follow-up study of the GAZEL cohort. J Psychiatr Res 47 (2013), 851–857.
48. [48] Limosin, F., Gasquet, I., Leguay, D., et al. Body mass index and prevalence of obesity in a French cohort of patients with Schizophrenia. Acta Psychiatr Scand 118 (2008), 19–25.
49. [49] Falissard, B., Mauri, M., Shaw, K., et al. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs. Int Clin Psychopharmacol 26:6 (2011), 291–302.
50. [50] Fleischhacker, W.W., Cetkovich-Bakmas, M., De Hert, M., et al. Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry 69 (2008), 514–519.
51. [51] Fan, Z., Wu, Y., Shen, J., et al. Schizophrenia and the risk of cardiovascular diseases: a meta-analysis of thirteen cohort studies. J Psychiatr Res 47 (2013), 1549–1556.
52. [52] Chaudhry, I.B., Jordan, J., Cousin, F.R., et al. Management in physical health in patients with schizophrenia. International insights. Eur Psychiatry 25 (2010), S37–S40.
53. [53] Saravane, D., Feve, B., Frances, Y., et al. Élaboration de recommandations pour le suivi somatique des patients atteints de pathologie mentale sévère. Encéphale 35 (2009), 330–339.
54. [54] Favrod, J., Barrelet, L., Efficacité de l'entraînement aux habiletés sociales avec les personnes atteintes de schizophrénie. Ther Comportementale Cogn 3:3 (1993), 84–94 [Masson].
55. [55] Rangaraj, J., Benarbia, F., Bothorel, A., et al. L'entrainement aux habiletés sociales (jeu de compétence selon Favrod) chez des patients schizophrènes. J Ther Comportementale Cogn 16:4 (2006), 146–150.
56. [56] Peyroux, E., Franck, N., RC2S: a cognitive remediation program to improve social cognition in schizophrenia and related disorders. Front Hum Neurosci, 8, 2014, 10.3389/fnhum.2014.00400 [Article 400, http://www.frontiersin.org/].
57. [57] Barrelet, L., Pellizzer, G., Ammann, L., Family expressed emotion and outcome of schizophrenics: a study in a French cultural environment. Arch Suisses Neurol Psychiatr 139 (1988), 27–34.
58. [58] Busnel, M., Leguay, D., Pollez, B., et al. L'Emploi, un droit à faire vivre pour tous. Rapport remis à M. Xavier Darcos, ministre du travail, des relations sociales, de la famille, de la solidarité, et de la ville. 2009.
59. [59] Leguay, D., Giraud-Baro, E., Lièvre, B., et al. Le Manifeste de Reh@b’ : propositions pour une meilleure prise en charge des personnes présentant des troubles psychiatriques chroniques et invalidants. Document élaboré et validé par le congrès de Versailles (13 et 14 mars 2008). Info Psychiatr 84:10 (2008), 885–893.
60. [60] Leguay, D., Rouillon, F., Azorin, J.M., et al. Évolution de l'autonomie sociale chez les patients schizophrènes selon les prises en charge. L’étude ESPASS. Encéphale 36 (2010), 397–407.
61. [61] Castel, R., Les métamorphoses de la question sociale. Une chronique du salariat. 1995, Fayard, Paris.
62. [62] Herman, G., Travail, chômage et stigmatisation. 2007, De Boeck, Bruxelles, Belgique [414 p.].
63. [63] Honneth, A., La lute pour la reconnaissance. 2002, Cerf. Coll. Passages, Paris [232 p.].
64. [64] Corbière, M., Le point sur la situation socioprofessionnelle des personnes atteintes de schizophrénie et autres troubles mentaux graves. Rev Que Psychol 29:1 (2008), 95–110.
65. [65] Dejours, C., Observations cliniques en psychopathologie du travail. 2010, PUF, coll. « Souffrance et théorie », Paris [160 p.].
66. [66] Direction Générale de la Cohésion Sociale (DGCS), Caisse Nationale de Solidarité pour l'Autonomie (CNSA), Démarche expérimentale d’évaluation de l'employabilité des personnes handicapées. Rapport final. 2013, Rapport de fin d'expérimentation DGCS/CNSA, Paris [164 p.].
67. [67] Provencher, H., Keyes, C.L.M., Une conception élargie du rétablissement. Info Psychiatr 86:7 (2010), 579–589.
68. [68] Anthony, W., Cohen, M., Farkas, M., et al. Psychiatric rehabilitation. Center for Psychiatric Rehabilitation, Boston University, traduction française, la réhabilitation psychiatrique. 2004, Socrate-Promarex Éditions, Charleroi.
69. [69] Deleu, G., Où nous mène la réhabilitation psychiatrique ?. 2012, Socrate Éditions Promarex, Charleroi.
70. [70] Deegan, P.E., The importance of personal medicine: a quantitative study of resilience in people with psychiatric disabilities. Scand J Public Health 33 (2005), 29–35.